<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00167934</url>
  </required_header>
  <id_info>
    <org_study_id>K23MH067795</org_study_id>
    <secondary_id>K23MH067795</secondary_id>
    <secondary_id>DAHBR AK-TNET1</secondary_id>
    <nct_id>NCT00167934</nct_id>
  </id_info>
  <brief_title>Determining Metabolic Effects of Valproate and Antipsychotic Therapy</brief_title>
  <official_title>Metabolic Effects of Valproate and Antipsychotic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the metabolic processes responsible for high levels of blood
      glucose, metabolism disorders, and weight gain in people with schizophrenia who have been
      treated with antipsychotic medications in combination with valproate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project aims to study the whole-body metabolic processes responsible for hyperglycemia,
      dyslipidemia and increased adiposity in schizophrenia patients treated with antipsychotic
      medications in combination with valproate. The project hypothesizes that combined treatment
      with valproate and antipsychotic medications will decrease insulin sensitivity at the level
      of skeletal muscle, liver and adipose tissue, in comparison to antipsychotic monotherapy. The
      decrease in insulin sensitivity is hypothesized to be associated with defects in glucose and
      lipid metabolism and increased adiposity

      Treatment effects of antipsychotic/valproate combination therapy on different components of
      insulin secretion and action, and treatment effects on abdominal versus peripheral adiposity,
      are unknown despite the availability of gold-standard methods and the prognostic significance
      of these issues. Relevant data are needed to target basic research, to identify the potential
      for acute and long-term complications, and to plan therapeutic interventions. The following
      specific aims will be addressed in non-diabetic schizophrenia patients treated with atypical
      antipsychotics who will be randomized to open label treatment with either valproate or no
      adjuvant. Evaluations are performed at baseline and 3 months of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Total Body Fat Composition Using Dual Energy X-ray Absorptiometry at 12 Weeks</measure>
    <time_frame>Measured at baseline and Week 12</time_frame>
    <description>Change in body composition (total body fat) was assessed using dual energy x-ray absorptiometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of Medication on Insulin Secretion at Skeletal Muscle (Glucose Disposal)</measure>
    <time_frame>Measured at baseline and Week 12</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50% of participants will receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50% of participants will receive Depakote ER</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproate</intervention_name>
    <description>Depakote ER 500 mg to 3000 mg taken every night</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Depakote ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo given at same frequency as Valproate</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV criteria for schizophrenia, any type, treated with the same antipsychotic
             for at least 6 months

          -  No antipsychotic medication dose changes for 1 month, and no other medication changes
             for 1 month prior to study entry

        Exclusion Criteria:

          -  Meets DSM-IV criteria for substance abuse within 3 months of study entry

          -  Involuntary legal status (as per Missouri law)

          -  Any serious medical disorder that may confound the assessment of relevant biologic
             measures or diagnosis, including: significant organ system dysfunction, metabolic
             diseases, type 1 or 2 diabetes mellitus, pregnancy, endocrine disease, coagulopathy,
             anemia, or acute infection

          -  Currently taking more than one antipsychotic medication

          -  Currently taking prescription medications (except certain psychotropic medications as
             discussed below), including oral contraceptive pills, any glucose lowering agent,
             lipid lowering agent, exogenous testosterone, recombinant human growth hormone, or any
             other endocrine agent that might confound substrate metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan W. Haupt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.psychiatry.wustl.edu/</url>
    <description>Click here for the Washington University Department of Psychiatry</description>
  </link>
  <reference>
    <citation>Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry. 2001;62 Suppl 27:15-26; discussion 40-1. Review.</citation>
    <PMID>11806485</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <results_first_submitted>November 18, 2015</results_first_submitted>
  <results_first_submitted_qc>January 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2020</results_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Metabolic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>50% of participants will receive placebo</description>
        </group>
        <group group_id="P2">
          <title>Experimental</title>
          <description>50% of participants will receive Depakote ER</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline population consists of those participants who enrolled and completed the study. In other words, these are the participants that are included in the analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>50% of participants will receive placebo</description>
        </group>
        <group group_id="B2">
          <title>Experimental</title>
          <description>50% of participants will receive Depakote ER</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.6" spread="10.1"/>
                    <measurement group_id="B2" value="41.3" spread="8.4"/>
                    <measurement group_id="B3" value="40.9" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total Body Fat Composition Using Dual Energy X-ray Absorptiometry at 12 Weeks</title>
        <description>Change in body composition (total body fat) was assessed using dual energy x-ray absorptiometry</description>
        <time_frame>Measured at baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>50% of participants will receive placebo</description>
          </group>
          <group group_id="O2">
            <title>Experimental</title>
            <description>50% of participants will receive Depakote ER</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Body Fat Composition Using Dual Energy X-ray Absorptiometry at 12 Weeks</title>
          <description>Change in body composition (total body fat) was assessed using dual energy x-ray absorptiometry</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="2.13"/>
                    <measurement group_id="O2" value="2.03" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effects of Medication on Insulin Secretion at Skeletal Muscle (Glucose Disposal)</title>
        <time_frame>Measured at baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>50% of participants will receive placebo</description>
          </group>
          <group group_id="O2">
            <title>Experimental</title>
            <description>50% of participants will receive Depakote ER</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Medication on Insulin Secretion at Skeletal Muscle (Glucose Disposal)</title>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="1.23"/>
                    <measurement group_id="O2" value="-0.35" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At 12 Week Assessment</time_frame>
      <desc>An Adverse Event Form is administered to participants by a trained rater.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>50% of participants will receive placebo</description>
        </group>
        <group group_id="E2">
          <title>Experimental</title>
          <description>50% of participants will receive Depakote ER</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness/Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tiredness/Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Yingling</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>573-579-1412</phone>
      <email>yinglingm@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

